The Business Research Company’s report on the Exosome Diagnostic And Therapeutic Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the exosome diagnostic and therapeutic market in recent years?
The rising prevalence of chronic diseases is expected to propel the growth of the exosome diagnostic and therapeutic market going forward. Chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Diagnostic and therapeutic applications of exosomes act as possible biomarkers in cancer that provide more sensitive disease monitoring, making personalized medicine more reachable. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, there will be 142.66 million people with chronic diseases worldwide by the year 2050. Therefore, the rising prevalence of chronic diseases is driving the exosome diagnostics and therapeutics market.
Access Your Free Sample of the Global Exosome Diagnostic And Therapeutic Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12346&type=smp
What is the projected market size of the exosome diagnostic and therapeutic industry, and how is it expected to grow?
The exosome diagnostic and therapeutic market size has grown exponentially in recent years. It will grow from $0.47 billion in 2024 to $0.61 billion in 2025 at a compound annual growth rate (CAGR) of 30.1%. The growth in the historic period can be attributed to biological research advancements, the emergence of precision medicine, biomedical imaging innovations, cancer research and oncology, and healthcare industry investments
The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 28.0%. The growth in the forecast period can be attributed to growing clinical applications, integration with digital health technologies, supportive regulatory environment, gene editing and RNA therapeutics, and expanded role in immuno-oncology. Major trends in the forecast period include exosome-based drug discovery, biomimetic exosome engineering, commercialization of exosome products, exosome-loaded therapeutic cargo, and liquid biopsy for cancer screening.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12346&type=smp
Who are the key players driving competition in the exosome diagnostic and therapeutic market?
Major companies operating in the exosome diagnostic and therapeutic market include Thermo Fisher Scientific Inc., Lonza Group AG, Bio-Techne Corp., Miltenyi Biotec GmBH, Malvern Instruments Inc., BioVision Inc., System Biosciences LLC, Evox Therapeutics Ltd., ExCoBio Inc., BioCat GmbH, NanoSomix Inc., Exosome Diagnostics Inc., Capricor Therapeutic Inc., Aethlon Medical Inc., Codiak BioSciences Inc., NX Pharmagen Inc., Exiqon A/S, Aegle Therapeutic Corporation, AMS Biotechnology Ltd., Cell Guidance Systems, Ciloa, Sienna Diagnostics, Sistemic Inc., Theoria Science, Mantra Bio Inc.
What key trends are expected to drive the e-waste recycling and reuse services market during the forecast period?
Major companies operating in the exosome diagnostic and therapeutic market are developing innovative products, such as sample purification systems, to meet larger customer bases, increase sales, and increase revenue. A sample purification system is a set of processes and technologies designed to remove impurities and contaminants from a sample, such as DNA, RNA, proteins, or other biomolecules. For instance, in February 2023, Biological Dynamics Inc., a US-based biotechnology company, launched ExoVerita, an exosome-isolation platform for early disease surveillance and other applications. The ExoVita Pancreas assay detects particular exosomal protein indicators and has been shown to detect Stage 1 and Stage 2 pancreatic ductal adenoma carcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company will use this validation to test samples from the ExoLuminate registry trial (NCT05625529), which has started actively recruiting patients with high-risk PDAC to examine the test’s clinical value. Patients with clinical signs such as pancreatitis or known pancreatic lesions, individuals with a genetic or familial propensity, and newly diagnosed diabetics over 50 are also eligible.
Which key geographies are driving the growth of the exosome diagnostic and therapeutic market?
North America was the largest region in the exosome diagnostic and therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exosome diagnostic and therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
What are the key segments driving growth in the exosome diagnostic and therapeutic market?
The exosome diagnostic and therapeutic market covered in this report is segmented –
1) By Product: Instruments, Software, Reagents And Kits
2) By Application: Diagnostics, Therapeutic
3) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Hospitals And Clinics, Other End Users
Subsegments:
1) By Instruments: Exosome Isolation Systems, Characterization Instruments, Analysis Devices
2) By Software: Data Analysis Software, Exosome Profiling Software, Laboratory Management Software
3) By Reagents And KITS: Isolation KITS, Characterization Reagents, Assay KITS
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12346
What defines the structure and scope of the exosome diagnostic and therapeutic market?
Exosome diagnostics and therapeutic refer to using exosomes, tiny extracellular particles generated by cells, in diagnosis and therapy. Exosomes are used in exosome therapies as a method of targeted medication delivery for regenerative medicine.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
